The US has announced a phased tariff plan on generic drugs (0% for 2 years, then 100%, then 200%) to pressure foreign pharmaceutical companies to build manufacturing facilities in America, with India being particularly vulnerable as it supplies nearly 40% of generic medicines sold in the US by volume, representing $9.7 billion in exports. This policy demonstrates how global supply chain dependencies create both economic opportunities and strategic vulnerabilities for countries that dominate essential industries.
Install our extension to search inside any video instantly.
TRUMP LIVE: Trump Declares BIGGER WAR! America's BIGGEST TRADE ULTIMATUM IN HISTORY! Watch Now
Added:This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform, Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of formos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sunfarma, Sipla, Dr. Ready's, the message is simple.
Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform, Truth Social, announcing a new tariff plan, but this one on generic drugs. Not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for one year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the what? It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But and this is the important bit. Don't relax just yet.
Doctors and health experts in America are already worried saying that this kind of tariff could make medicines more expensive, cause shortages and force rationing. So this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, Sipla, Dr. Ready's, the message is simple. Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, Sipla, Dr. Ready's. The message is simple. Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the Straight of Hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the what? It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sunfarma, Sipla, Dr. Ready's, the message is simple.
Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform, Truth Social, announcing a new tariff plan, but this one on generic drugs. Not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried saying that this kind of tariff could make medicines more expensive, cause shortages and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, Sipla, Dr. Ready's, the message is simple. Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform, Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of formos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sunfarma, Sipla, Dr. Ready's, the message is simple.
Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform Truth Social, announcing a new tariff plan, but this one on generic drugs. Not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for one year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the what? It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried saying that this kind of tariff could make medicines more expensive, cause shortages and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, Sipla, Dr. Ready's, the message is simple. Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of war, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, Sipla, Dr. Ready's. The message is simple. Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the Straight of Hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the what? It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sunfarma, Sipla, Dr. Ready's, the message is simple.
Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform, Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of formos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sunfarma, Sipla, Dr. Ready's, the message is simple.
Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform, Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for one year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the what? It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But and this is the important bit. Don't relax just yet.
Doctors and health experts in America are already worried saying that this kind of tariff could make medicines more expensive, cause shortages and force rationing. So this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, Sipla, Dr. Ready's, the message is simple. Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform, Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, Sipla, Dr. Reddy's. The message is simple. Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the Straight of Hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the what? It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sunfarma, Sipla, Dr. Ready's, the message is simple.
Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, Sipla, Dr. Ready's, the message is simple. Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform, Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with a penalty. And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of formos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sunfarma, Sipla, Dr. Ready's, the message is simple.
Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform, Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for one year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war, missiles, the straight of armos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the what? It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a two-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But and this is the important bit. Don't relax just yet.
Doctors and health experts in America are already worried saying that this kind of tariff could make medicines more expensive, cause shortages and force rationing. So this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, Sipla, Dr. Ready's, the message is simple. Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform, Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, Sipla, Dr. Ready's. The message is simple. Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the Straight of Hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the what? It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, SPLA, Dr. Ready's the message is simple.
Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached. And he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. This makes India vulnerable to America. Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. Two years on the clock. Let's see who blinks first. What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, Sipla, Dr. Ready's the message is simple. Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform, Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of formos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sunfarma, Sipla, Dr. Ready's, the message is simple.
Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform Truth Social, announcing a new tariff plan, but this one on generic drugs. Not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for one year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But and this is the important bit. Don't relax just yet.
Doctors and health experts in America are already worried saying that this kind of tariff could make medicines more expensive, cause shortages and force rationing. So this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, Sipla, Dr. Ready's, the message is simple. Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, Sipla, Dr. Ready's. The message is simple. Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war, missiles, the straight of armos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars. Viewers, so why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the what? It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, SPLA, Dr. Ready's the message is simple.
Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform, Truth Social, announcing a new tariff plan, but this one on generic drugs. Not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sun Pharma, Sipla, Dr. Ready's the message is simple. Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform, Truth Social, announcing a new tariff plan, but this one on generic drugs, not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for 1 year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of war, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But now, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38% of everything India exports in pharma to the entire world.
So picture this viewers, more than one in every $3 India earns from selling medicines abroad comes from just one country, the United States of America.
That is why people call India the pharmacy of the world. It is not just a nice nickname. It is literally true.
We're talking about medicines for diabetes, for cancer, infections, mental health, real drugs, for real patients all across America. So, is India in trouble right now? Well, not immediately. And here is why. India has got a 2-year buffer before any tariff even kicks in. And there is a bit of a safety net too. Back in February, India and the United States signed a trade deal that specifically promised India some protection on generic drugs. So there is a document somewhere that is supposed to have India's back in this tariff war. But, and this is the important bit, don't relax just yet.
Doctors and health experts in America are already worried, saying that this kind of tariff could make medicines more expensive, cause shortages, and force rationing. So, this is not just an India problem. If this tariff actually kicks in down the line, ordinary Americans could end up paying more for their daily medicines too.
For Indian pharma companies, there is of course a problem. Think Sunfarma, Sipla, Dr. Ready's, the message is simple.
Either set up shop in America now or get ready to pay a massive tax later. Two years sounds like plenty of time, but it's really not. Building a pharma factory and getting it approved can take years on its own.
So, the bottom line, what's really going on here? Well, this is classic Donald Trump. Turn trade policy into a countdown. Zero now, 100 later, 200 after that. It is less a policy and more of an ultimatum with a deadline attached and he is playing it out in public right now. And for India, this is a good reminder. Being the world's pharmacy comes with a catch. The same thing that makes India valuable to America is also what makes India vulnerable to America.
Because when you supply that much of someone's medicine, they can always turn around and use that against you. That is exactly what Donald Trump is doing. The countdown starts August 1st. 2 years on the clock. Let's see who blinks first.
What do you think about it? Tell us in the comment section below.
This is the India vector with Nikita Kapoor.
>> They said it would never happen. For months, the Donald Trump administration insisted that generics were safe, untouched, exempted, off the table.
Well, forget that because as of now, Washington has just fired its biggest shot yet at the world's pharmacy. Let's start with what actually happened.
US President Donald Trump posted on his platform Truth Social, announcing a new tariff plan, but this one on generic drugs. Not the fancy branded ones, the cheap everyday medicines, the ones for blood pressure, for diabetes, for infections. And here's the plan. For the next 2 years, viewers, until August 2028, there is no tariff at all. Zero.
Then for one year after that it jumps to 100%. And after that it goes to 200%.
Think of it like a landlord giving you 2 years of free rent then doubling it and then doubling it again. That is basically what Donald Trump is doing to any drug company that keeps making generics outside America. The whole point, he says, is to push these companies to build factories inside the United States of America instead of importing from abroad. And if they don't, they get hit with the penalty.
And just to be clear, this does not touch the expensive patented drugs. That policy stays exactly the same as before.
This is about generics. Now, here's the part that is kind of wild. This announcement dropped in the middle of an allout US Iran war. Missiles, the straight of hormos, ceasefire talks, the works. You would think that Donald Trump's entire focus would be the Gulf right now. But no, he still found a moment to drop a bombshell on the pharmaceutical industry. That tells you something. Trade wars don't take a break even during real wars, viewers. So why should you care? Because almost nine out of every 10 medicines Americans take are generics, not the ones in the fancy TV ads, the basic stuff people take every single day. And a huge chunk of that basic stuff, it comes from one single country, India. India is not just a supplier. India basically keeps America's medicine cabinet stocked.
Almost 40% of all generic medicines sold in the United States by volume come from India. That is not a small number. That is nearly half. In dollar terms, India sold $9.7 billion dollars worth of medicines to the US last year alone, which is about 38%
Related Videos
3:00
Economics
Campagne CA$$$H Pourquoi revendiquer un meilleur financement? (version nov.2022)
trpocb
153 views•2022-11-03
0:13
Economics
Modern Privilege and Perspective
Samvoyage1
858 views•2026-04-16
57:45
Economics
Davos 2019 - Global Economy in Transition
wef
19K views•2019-02-09
6:29
Economics
The Vertical Long-Run Aggregate Supply (LRAS) Curve
educo-mr
908 views•2025-12-10
48:29
Economics
Stimulus Loans and Shadow Banking: The Growth of Chinese Financial Markets and the US Experience
BFIVideos
3K views•2019-05-23
11:54
Economics
Institute Insights: The Implications of Interest Rate Addiction
UNCKenanInstitute
100 views•2019-09-25
27:05
Economics
The Grouse Shooting Problem
tgsoutdoors
73K views•2019-09-08
1:58
Economics
Cost to raise child from birth to 18 has risen 36% since 2023
kgun9
198 views•2025-05-14
Trending
13:25
Business
Playstation NO DISC/NO BUY Fight Is Over...
DavidJaffeGames
4K views•2026-07-23
16:52
Anthropology
Americans Confused in Australia for 17 Minutes Straight
IWrocker
17K views•2026-07-23
7:38
Blockchain & Crypto
Bitcoin Social Interest: Dozens of us Left
benjaminjcowen
12K views•2026-07-23
11:32
Business
Tesla Profits Plunge & SpaceX Stock Continues Fall
TheJohnJohnstonLounge
6K views•2026-07-23